Abstract. Human low density lipoprotein (LDL, d = 1.020-1.050 g/ml) inhibits mitogen-stimulated T lymphocyte DNA synthesis. Because both LDL and transferrin bind to specific cell surface receptors and enter cells by the similar means of receptor-mediated endocytosis, and because transferrin is necessary for lymphocyte DNA synthesis, we investigated the possibility that LDL may inhibit mitogen-stimulated lymphocyte responses by interfering with transferrin metabolism. LDL inhibited mitogen-stimulated lymphocyte [3H]thymidine incorporation in a concentration-dependent manner. The degree of inhibition was most marked in serum-free cultures, but was also observed in serum-containing cultures. The addition of transferrin not only augmented mitogeninduced lymphocyte [3H]thymidine incorporation in serum-free medium but also completely reversed the inhibitory effect of LDL in both serum-free and serumcontaining media. Similar results were obtained when lymphocyte proliferation was assayed by counting the number of cells in culture. Transferrin also reversed the inhibition of lymphocyte responses caused by very low density lipoproteins and by cholesterol. The ability of transferrin to reverse the inhibitory effect of lipoproteins was specific, in that native but not denatured transferrin was effective whereas a variety of other proteins were Portions of this work were presented at the Annual Meeting of the American Society for Clinical Investigation, Washington, DC, May 1983, and were published in abstract form in 1983, Clin. Res., 31:459a.
Introduction
The inhibitory effect of normal low density lipoprotein (LDL) on antigen-and mitogen-stimulated lymphocyte responses has been well described by a number of investigators (1) (2) (3) (4) (5) . LDL and other classes of lipoproteins have been shown to suppress lymphocyte [3H]thymidine incorporation stimulated by both allogeneic cells and mitogens (1) (2) (3) (4) (5) . However, the mechanism whereby LDL is inhibitory has not been completely elucidated. We have recently demonstrated that LDL does not inhibit initial lymphocyte activation and blast transformation but does inhibit lymphocyte DNA synthesis and subsequent proliferation (5) . These observations suggest that suppression of DNA synthesis is the major inhibitory effect of LDL.
It has been previously shown that transferrin is required for mitogen-induced lymphocyte DNA synthesis (6) (7) (8) . In addition, mitogenic stimulation results in the appearance of transferrin receptors on activated lymphocytes (9) (10) (11) (12) . Furthermore, both transferrin and LDL bind to specific cell surface receptors and enter cells by the process ofreceptor-mediated endocytosis (13) . Although LDL-mediated inhibition of lymphocyte responses may not require endocytosis of LDL (4) and may involve receptors that are distinct from the classic high affinity receptors involved in cholesterol metabolism (3, 4) , it is possible that LDL inhibits mitogen-induced lymphocyte DNA synthesis by altering transferrin metabolism. The following experiments examined this possibility.
Methods
Isolation of lipoproteins. Human LDL (d = 1.020-1.050 g/ml) was isolated from plasma of normal fasting adults, using a Beckman preparative ultracentrifuge (Beckman Instruments, Palo Alto, CA) as previously described (5) . Very low density lipoprotein (VLDL, d < 1.006 g/ml), intermediate density lipoprotein (IDL, d = 1.006-1.019 g/ml),' and a combined VLDL + IDL preparation (d < 1.020 g/ml) were isolated in a similar manner. High density lipoprotein (HDL) was isolated as previously detailed (14) . In preliminary studies, three different density preparations, d = 1.050-1.230 g/ml, d = 1.095-1.230 g/ml, and d = 1.125-1.230 g/ml were isolated and were found to be similar in their effects on mitogen-stimulated lymphocyte responses. Protein concentrations were determined by the method of Lowry et al. (15) and total cholesterol concentration was measured by the enzymatic method of Roeschlau et al. (16) . Each individual LDL preparation is designated by a subscript (LDLx).
Reagents. Transferrin, nitrilotriacetate, catalase, fatty-acid free bovine serum albumin (BSA), ovalbumin, lactoperoxidase, and hydrogen peroxide were purchased from Sigma Chemical Co., St. Louis, MO. Cholesterol was purchased from Eastman Kodak Co., Rochester, NY. IodoGen (1,3,4,6-tetrachloro-3a,6a-diphenylglycoluril) was obtained from Pierce Chemical Co., Rockford, IL, and chloroform from Mallinkrodt Inc., St. Louis, MO. With the exception ofcholesterol, all reagents which were added directly to the cultures were dissolved in Hanks' balanced salt solution. An equal volume of Hanks' solution was added to control cultures. Cholesterol was dissolved in ethanol and added directly to the cultures. An Techniques ofcell preparation and culture. Peripheral blood mononuclear cells (PBM) were separated from heparinized venous blood of healthy young adults by centrifugation on a layer of sodium diatrizoate/ Ficoll as previously described (17) . In some experiments, partially monocyte-depleted T cell-enriched populations were obtained as pre-1. Abbreviations used in this paper: Dil, 3,3'-dioctadecylindocarboncyanine; FACS, fluorescence-activated cell sorter, FH, familial hypercholesterolemia; HS, human serum; IDL, intermediate density lipoprotein; PBM, peripheral mononuclear cell; PHA, phytohemagglutinin; SPA, staphylococcal protein A. viously described (18) . Cells were cultured in medium RPMI 1640 (Microbiological Associates, Walkersville, MD), with added L-glutamine (0.3 mg/ml), gentamicin (10 ,g/ml), and penicillin G (200 U/ml). In some experiments the medium was further supplemented with 1% human serum (HS). This concentration has been shown to result in lymphocyte responses similar to those obtained with 10% fetal bovine serum (5 (17, 19) . All (22) . Partially monocyte-depleted lymphocytes were incubated for 8 h at 370C in serum-free medium with DiI-LDL with or without an excess of unlabeled LDL. The cells were then washed, resuspended, and analyzed with the fluorescence-activated cell sorter to quantitate cell-associated fluorescence.
Radiolabeling of transferrin. Human transferrin was labeled with 1251 by means of lactoperoxidase (23) or Iodo-Gen (24) as previously described. Briefly, lactoperoxidase-catalyzed radioiodination was carried out using 50 tg of transferrin, 0.5 mCi of carrier-free 1251I as NaI (sp act 15 Ci/mg, Amersham Corp., Arlington Heights, IL), 5 eg of lactoperoxidase, and 0.003% hydrogen peroxide as described (23) . Iodo-Gencatalyzed radioiodination was carried out using 50 Mg of transferrin and 0.2 mCi of carrier-free 1251 as Nal as detailed (24) . Unbound 125I was removed by extensive dialysis. The specific activity ofthe radioiodinated transferrin was approximately 2 uCi/ug in both cases.
Measurement ofLDL binding of'25I-transferrin. A possible association of LDL with 251I-transferrin was quantitated by the following methods. First, LDL (2 mg protein) was incubated with 0.5 Mg '25I-transferrin for I h and then the density of the preparation was adjusted to 1.095 g/ml with solid KBr. The LDL was reisolated by flotation centrifugation and the radioactivity in the lipoprotein and in the infranatant was measured.
In another procedure, LDL (180 jg protein) was incubated with 0.5 Mg '251-transferrin for 48 h at 40C. The sample was then subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis as previously described (25) . In a final procedure, insoluble undenatured LDL was prepared and the binding of 1251-transferrin was quantitated. SPA-Sepharose was preincubated with rabbit anti-human ,-lipoprotein antiserum for 1 h at 40C. As a control SPA-Sepharose was preincubated with normal rabbit serum or rabbit anti-human transferrin antiserum. An aliquot of each ofthese was then incubated with LDL for 24 h at 40C. Quantitation of cholesterol concentration confirmed that LDL (30 Mg protein/ml) bound to the rabbit anti-/-lipoprotein SPA-Sepharose but not other antibody-coated SPA-Sepharose preparations. '251I-transferrin (1 gg/ml) was then incubated for 1 h with each preparation and the radioactivity bound to the sepharose was quantitated.
Radioiodinated transferrin binding assays. The binding reactions were carried out in 12 X 75-mm glass tubes (American Scientific Products Div., American Hospital Supply Corp., McGaw Park, IL) in the presence of 1% BSA. The cell preparations used included both PBM and T cellenriched populations prepared as described previously by sequential glass adherence and passage over nylon wool columns (18) . The cell populations were incubated for 24 h with or without PHA in 17 X 100-mm polypropylene tubes (Falcon Div., Becton, Dickinson & Co., Cockeysville, MD), with each tube containing 2-4 X 106 cells in 2 ml of culture medium either supplemented with 0.1% HS or without serum.
In some experiments, LDL (200-360 M&g protein/ml) was also included in the incubation medium. After extensive washing, the cells were resuspended in RPMI 1640, containing 1% bovine serum albumin and 10 mM Hepes, pH 7.4 at 5-10 X 10 cells/ml. Viability was >90% as measured by uptake of fluorescein diacetate and exclusion of ethidium bromide (26) . Preliminary experiments established that binding assays were reproducible using 1-2 X 106 cells and incubation for 60 min with the radiolabeled ligand. Unbound ligand was removed by passage of cells through a 200-Ml density cushion of dibutyl phthalate and dinonyl phthalate as detailed previously (27) . Binding assays were carried out in triplicate and in each experiment an additional assay was run containing a 500-fold excess of unlabeled transferrin to allow correction for nonspecific binding of ligand.
Results
LDL inhibits lymphocyte responses. Initial experiments were carried out to compare the effect of LDL on lymphocyte responses in serum-free medium with those obtained when cells were cultured in medium supplemented with serum. As seen in Table I Mg/ml. Similar variability has been described previously for cultures in serum-containing medium (5) . These initial studies demonstrated that LDL inhibited lymphocyte responses in a qualitatively similar manner, regardless of the culture medium. However, the inhibition noted in serum-free medium was significantly greater than that observed in serum-containing cultures or those supplemented with Table II , the addition of transferrin significantly increased (P < 0.001) the response of lymphocytes cultured in serum-free medium. Moreover, when transferrin was added to cultures containing LDL, the inhibitory effect of LDL was markedly decreased. At the highest concentration of transferrin (50 jg/ml) the inhibition by LDL was completely prevented. Furthermore, the combination ofLDL and transferrin (50 jig/ml) resulted in significant enhancement of mitogen-induced lymphocyte DNA synthesis over that observed with transferrin alone. Similar results were obtained with all LDL preparations tested. In fact, lymphocyte responses in serumfree medium supplemented with transferrin and LDL were equal to or greater than those observed in serum-containing cultures.
When lymphocytes were cultured in serum-free medium, the concentration of LDL required to inhibit mitogen-stimulated lymphocyte responses by 50% was significantly increased by the addition ofas little as 0.5 ig/ml transferrin (Table III) . In serumsupplemented cultures (containing -20 jig/ml of transferrin from 1% HS), a higher concentration of LDLM was required to inhibit lymphocyte responses to a similar degree (Table III) and addition of low concentrations of transferrin had no significant effect. However, in both serum-free medium and cultures supplemented with 1% HS, no inhibition was caused by LDL in the presence of 50 Mg/ml of transferrin.
Transferrin reverses inhibition by other lipoproteins and cholesterol. We next examined whether transferrin was able to prevent the inhibitory effects oflipoproteins other than LDL. Both (Table IV) . Transferrin (50 jg/ml) also reversed the inhibitory effect of cholesterol. Mevalonate did not reverse the inhibition, indicating that oxygenated sterol contamination was not the cause of the inhibition ( 17, 19, 34 Transferrin also prevented LDL-mediated inhibition of mitogen-stimulated lymphocyte proliferation in serum-free medium (Fig. 1) . Without the addition oftransferrin to the serumfree medium, there was no detectable increase in cell number after mitogenic stimulation. When transferrin alone was added, a small increase (two to threefold) in cell number was observed, indicating that it had permitted a modest degree of PHA-stimulated lymphocyte proliferation. The smallest concentration of LDL enhanced the proliferative response supported by all concentrations of transferrin with the degree of proliferation observed being dependent on the concentration of transferrin. With the addition of increasing concentrations of LDL, PHAstimulated lymphocyte proliferation was inhibited in cultures containing low concentrations of transferrin (0.5 --5 jig/ml). 50 jg/ml of transferrin completely prevented LDL-mediated inhibition of lymphocyte proliferation. PHA-stimulated lymphocyte proliferation in serum-free cultures containing LDL and 50 jig/ml transferrin was greater than in cultures supplemented with 1% HS (LDL + transferrin = 406,300±5,100 cells/ well after 7 d, 1% HS = 296,000±29,700 cells/well, mean±SEM, n = 4, 50,000 cells/well initially cultured).
Native but not denatured transferrin reverses the inhibitory effect of LDL. The studies outlined above demonstrated that transferrin reversed LDL-modulated inhibition. However, they did not establish the specificity ofthis effect. We next determined whether denatured transferrin was able to prevent the inhibition. In these experiments, an aliquot of transferrin was denatured by heating to 100°C for 60 min. The resultant preparation was unchanged in protein concentration, determined by the method ofLowry et al. (15) . However, the protein was no longer identified by a rabbit anti-human transfenin antiserum. Moreover, de- Fig. 2 A, there was measurable uptake of DiI-LDL in unstimulated cells, which was markedly increased in the PHA-activated cell population. As shown in Fig. 2 B, uptake of DiI-LDL was markedly inhibited by the addition of an excess of unlabeled LDL. By contrast, transferrin (50g g/ml) had no effect on the uptake of DiI-LDL by the cells (Fig. 2 B) . Thus (9, 10) . During the process of activation, specific receptors for transferrin first appear 20-24 h after the commencement of mitogenic stimulation. The monoclonal antibody 5E9 was used to identify transferrin receptor antigen on activated lymphocytes after a 24-h incubation. As shown in Table X , PHA stimulation markedly increased the number of cells that were 5E9 positive, indicating that the cells had acquired transferrin receptor antigen. When LDL was present during the process of activation, there was no effect on the appearance of the specific receptor antigen nor was there a decrease in receptor antigen density (Fig. 2) equilibration and remained during the assay. As shown in Table  XI The rationale for these studies was the evidence that cellular uptake of both LDL and transferrin involved the process of receptor-mediated endocytosis. However, previous evidence has suggested that LDL need not be internalized to inhibit lymphocyte activation and that the classic high affinity LDL receptors may not be involved (3, 4) . Therefore, the possibility that LDL inhibited lymphocyte DNA synthesis without binding to its specific high affinity cell-surface receptor was examined. In order to study this question, PBM were isolated from venous blood obtained from a 6-yr-old child with LDL-receptor negative familial hypercholesterolemia (FH). As shown in Table XII Transferrin that was substantially iron-free (~-34 jsg ofiron/ g transferrin) was effective in preventing inhibition of LDL and was able to enhance mitogen-stimulated [3H]thymidine incorporation in serum-free medium. The latter finding confirms previous reports (7, 8) . In that the medium used in these experiments contains -160 ng of iron/ml, the possibility exists that transferrin becomes optimally saturated with iron under the culture conditions utilized. The (4) or engagement of the classic high affinity LDL receptor (3, 4) . Binding to specific receptors followed by endocytosis does, however, appear to be necessary for transferrin to promote DNA synthesis (13, 36 Further insight into the mechanism whereby LDL inhibits lymphocyte responses was provided by the experiments utilizing cells lacking specific high affinity receptors for LDL. These studies clearly establish that the inhibitory effect ofLDL does not require binding to high affinity cell surface receptors specific for cholesterol transport by native LDL. Harmony and Hui (4) have reported that lymphocytes from patients with receptor-negative familial hypercholesterolemia have normal binding of LDL to "immunosuppression receptors." The nature and specificity of such putative receptors remain unclear. Moreover, it has not been established that "immunosuppression receptors" reside within coated pits. Regardless, the finding implies that LDL would be expected to exert a similar degree ofsuppression when tested on lymphocytes from patients with FH. This expectation was confirmed by the current studies. Harmony and Hui (4) also observed that internalization of LDL was not required for inhibition of mitogen-stimulated lymphocyte responses. Surfaceassociated LDL may alter lymphocyte plasma membrane function perhaps by exchange of lipid moieties such as cholesterol and thereby interfere with lymphocyte responses. The current studies suggest that cholesterol is the lipid that is most likely to explain the inhibitory effect of LDL. The reports by other investigators that lipid-depleted LDL may also be inhibitory suggest the possibility that inhibitory mechanisms other than interference with transferrin metabolism may be involved. Because we have not found any native LDL preparations whose inhibitory effects were not reversed by transferrin, it is possible that the process of lipid depletion may introduce additional inhibitory effects not shared by native LDL. Moreover, the possibility that apoproteins found associated with higher density lipoproteins may contribute to the inhibitory effects reported by others deserves consideration. In this regard, we have found in preliminary experiments that purified apoprotein E peptides (kindly provided by Dr. K. Weisgraber) inhibit mitogen-stimulated lymphocyte DNA synthesis but that the effect is not reversed by transferrin.
There are a number of mechanisms whereby LDL may inhibit transferrin metabolism without altering receptor expression or initial receptor binding. Recent reports indicate that both transferrin and its receptor are recycled after endocytosis (36, 37) . LDL may interfere with the recycling process for either the transferrin receptor or for transferrin itself. The means by which this is accomplished could involve transfer of LDL cholesterol to the lymphocyte membrane. Changes in plasma membrane cholesterol have been shown to alter both membrane fluidity and transferrin binding (38, 39) . For example, cholesterol depletion has been found to increase both membrane fluidity and the binding oftransferrin to cell (38) and model membranes (39) . We have demonstrated that cholesterol alone inhibits PHAinduced lymphocyte [3H]thymidine incorporation in serum-free medium and the inhibitory effect is prevented by transferrin. This result supports the conclusion that changes in membrane cholesterol may be involved in the mechanism ofthe inhibition.
Whereas transferrin may be required for DNA synthesis, it may also be necessary for cell division (40) (Table I) , inhibited lymphocyte proliferation by nearly 40% (P < 0.02, Table V ). The possibility remains that LDL exerts an additional inhibitory effect by blocking transferrindependent cell division, thereby preventing continuing proliferation of responding lymphocytes.
In summary, the results indicate that LDL inhibits mitogenstimulated lymphocyte DNA synthesis and proliferation. In addition, they indicate that the mechanism whereby LDL is inhibitory is by interference with transferrin metabolism. This model system should be useful in dissecting the mechanism whereby LDL modulates growth of stimulated lymphocytes.
